TACSTD2 and neoplasm: Interestingly, similar to that of TP53, the mode of TACSTD2 activation is quite unique, compared to that of most other tumor suppressors; 82.5% of TACSTD2 mutations are truncating/nonsense mutations, as a C → T at nucleotide 352 replaces the glutamine at codon 118 with a Q118X stop codon [29].